Medulloblastoma Cell Models for Research

Medulloblastoma is the most common malignant brain tumor in children, accounting for approximately 20% of all pediatric brain tumors. The annual incidence is about 0.5 per 100,000 children under 15 years of age, with a slight male predominance. The 5-year survival rate has improved to over 70% with current multimodal therapy, but survivors often suffer from long-term neurocognitive and endocrine sequelae. Recurrent and metastatic disease remain challenging, with a 5-year survival of less than 20% for relapsed patients. Risk factors include genetic syndromes such as Gorlin syndrome (PTCH1 mutations) and Turcot syndrome (APC mutations), but most cases are sporadic. (Source: WHO Classification of Tumours of the Central Nervous System, 2021; NCI PDQ).

Medulloblastoma is an ideal model for studying developmental biology and oncogenesis because it arises from distinct cell populations in the developing cerebellum. The disease is classified into four major molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles, clinical outcomes, and cellular origins. This heterogeneity provides a rich platform for investigating how specific genetic alterations drive tumor initiation and progression. Public datasets such as TCGA and GEO offer extensive genomic and transcriptomic data, enabling researchers to identify novel therapeutic targets. Gene-edited cell models, particularly isogenic lines, allow precise dissection of the functional consequences of specific mutations in a controlled genetic background, addressing key questions about tumor suppressor and oncogene function.

Medulloblastoma arises from dysregulation of key developmental signaling pathways. The major pathways include:

• • WNT signaling: Activated in the WNT subgroup, often due to CTNNB1 mutations leading to stabilized beta-catenin. This pathway promotes cell proliferation and stemness.
• • SHH signaling: Aberrant activation in the SHH subgroup, frequently caused by mutations in PTCH1, SMO, or SUFU. This pathway is crucial for cerebellar granule neuron precursor proliferation.
• • NOTCH signaling: Involved in maintaining neural stem cell populations; dysregulation contributes to tumor growth in various subgroups.
• • PI3K/AKT/mTOR: Frequently activated in Group 3 and Group 4 tumors, promoting cell survival and metabolism.
• • MYC signaling: Amplification of MYC or MYCN is common in Group 3 and Group 4, driving aggressive proliferation.

Data from TCGA and COSMIC databases.

The molecular subgroups exhibit distinct signaling dependencies:

• • WNT subgroup: Canonical WNT signaling is constitutively active. Key nodes include beta-catenin, TCF/LEF transcription factors, and downstream targets like MYC and Cyclin D1.
• • SHH subgroup: The SHH pathway is aberrantly activated. Key nodes include PTCH1, SMO, SUFU, GLI transcription factors, and downstream targets like MYCN and BCL2.
• • Group 3: Characterized by MYC amplification and activation of the PI3K/AKT/mTOR pathway. Key nodes include MYC, PI3K, AKT, mTOR, and downstream effectors like Cyclin D2.
• • Group 4: Often exhibit mutations in chromatin remodeling genes (KDM6A, ZMYM3) and activation of NF-κB signaling. Key nodes include KDM6A, NF-κB, and its downstream targets.

Organoids derived from patient tumors or induced pluripotent stem cells (iPSCs) offer a more physiologically relevant 3D culture system, preserving tumor heterogeneity and allowing for drug testing in a more realistic microenvironment.

Animal models are essential for studying medulloblastoma in vivo. Common models include:

• • Patient-derived xenografts (PDX): Implantation of patient tumor cells into immunodeficient mice, preserving the molecular and genetic features of the original tumor.
• • Genetically engineered mouse models (GEMM): Mice with conditional knock-in of activating mutations (e.g., SmoM2) or knockout of tumor suppressors (e.g., Ptch1) to recapitulate specific subgroups.
• • Induced models: Use of viral vectors or transposons to introduce oncogenes (e.g., MYC) into neural stem cells, leading to tumor formation.

CRISPR-based gene editing has revolutionized the creation of isogenic cell models. By introducing precise mutations into a parental cell line, researchers can generate knockout or knock-in lines that differ only in the targeted gene, allowing for direct functional comparisons. For example:

• • A TP53 knockout DAOY cell line can be used to study the role of p53 in drug resistance.
• • A CTNNB1 S33Y knock-in DAOY cell line can model WNT activation in a SHH background.

These gene-edited models are commercially available as sequence-verified, clonally derived cell lines, ensuring reproducibility and accelerating research. They are essential for validating drug targets, studying resistance mechanisms, and screening for synthetic lethal interactions.

Gene-edited cell lines are powerful tools for functional genomics. For example:

• • Knockout of a candidate tumor suppressor gene (e.g., KDM6A) in a DAOY cell line can reveal its role in cell proliferation and migration.
• • Knock-in of an oncogenic mutation (e.g., MYC amplification) into a non-tumorigenic cell line can transform it, allowing study of oncogene addiction.

These models enable researchers to assign function to genes identified in genomic studies, bridging the gap between genetic alterations and phenotype.

Isogenic cell line pairs (parental vs. gene-edited) are ideal for drug screening and resistance studies. For instance:

• • A PTCH1 knockout DAOY cell line can be used to test SHH pathway inhibitors, such as vismodegib, and identify resistance mechanisms.
• • A TP53 knockout line can be used to screen for drugs that selectively kill p53-deficient cells, exploiting synthetic lethality.

By comparing drug responses between isogenic lines, researchers can identify specific genetic determinants of drug sensitivity and resistance.

CRISPR-based screens using gene-edited cell lines can identify biomarkers for diagnosis and prognosis. For example:

• • A genome-wide CRISPR knockout screen in a MYC-amplified medulloblastoma cell line can identify genes whose loss sensitizes cells to a particular drug, revealing potential predictive biomarkers.
• • Isogenic lines with different mutations can be used to identify secreted proteins or cell surface markers that distinguish subgroups, aiding in liquid biopsy development.